Applications of Hemagglutinating Virus of Japan in therapeutic delivery systems

Expert Opinion on Drug Delivery

Volumn 5, Issue 2, 2008, Pages 221-233

  Kaneda, Yasufumi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Drug delivery; Fusion; Gene therapy; Hemagglutinating Virus of Japan; Immunotherapy

Indexed keywords

BLEOMYCIN; CISPLATIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KANAMYCIN; ONCOLYTIC PARAMYXOVIRUS; ONCOLYTIC VIRUS; PLASMID DNA; RAD51 PROTEIN; SCATTER FACTOR; SMALL INTERFERING RNA; VIRUS VECTOR;

CELLULAR IMMUNITY; DNA REPAIR; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; ENTERITIS; GENE EXPRESSION; GENE LIBRARY; GENE TARGETING; GENE TRANSFER; HUMAN; NONHUMAN; PARAINFLUENZA VIRUS 1; REVIEW; VIRAL GENE DELIVERY SYSTEM; VIRUS ENVELOPE;

ANIMALS; DRUG DELIVERY SYSTEMS; GENE EXPRESSION; GENE SILENCING; GENE THERAPY; GENETIC VECTORS; IMMUNOTHERAPY; NEOPLASMS; SENDAI VIRUS;

EID: 39749085331     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.5.2.221     Document Type: Review

References (80)

1. Mulligan RC. The basic science of gene therapy. Science 1993;260(5110):926
2. Ledley FD. Nonviral gene therapy: the promise of genes as pharmaceutical products. Hum Gene Ther 1995;6(9):1129-44
3. Li S, Huang L. Nonviral gene therapy: promises and challenges. Gene Ther 2000;7:31-4
4. Lam PY, Breakefield XO. Hybrid vector designs to control the delivery, fate and expression of transgenes. J Gene Med 2000;2(6):395-408
5. Verma IM, Weitzman MD. Gene therapy: twenty-first century medicine. Ann Rev Biochem 2005;74:711-38
6. Wattiaux R, Laurent N, Wattiaux-De Coninck S, et al. Endosomes, lysosomes: their implication in gene transfer. Adv Drug Deliv Rev 2000;41(2):201-8
7. Zabner J, Fasbender AJ, Moninger T, et al. Cellular and molecular barriers to gene transfer by a cationic lipid. J Biol Chem 2005;280(13):12255-61
8. Kaneda, Y. Biological barriers to gene therapy. In: Amiji M, editor. Polymeric Gene Delivery. Florida. CRC Press; 2005. p. 29-42
9. Farhood H, Serbina N, Huang L. The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer. Biochim. Biophys Acta 1995;1235(2):289-95
10. El Ouahabi A, Thiry M, Pector V, et al. The role of endosome destabilizing activity in the gene transfer process mediated by cationic lipids. FEBS Lett 1997;414(2):187-92
11. Neu M, Fischer D, Kissel T. Recent advances in rational gene transfer vector design based on poly (ethylene imine) and its derivatives. J Gene Med 2005;7(8):992-1009
12. Seth P. Mechanism of adenovirus-mediated endosome lysis: role of the intact adenovirus capsid structure. Biochem Biophys Res Commun 1994;205(2):1318-24
13. Greber UF, Webster P, Weber J, et al. The role of the adenovirus protease on virus entry into cells. EMBO J 1996;15:1766-77
14. Zanta MA, Belguise-Valladier P, Behr JP. Gene delivery: a single nuclear localization signal peptide is sufficient to carry DNA to the cell nucleus. Proc Natl Acad Sci USA 1999;96:91-6
15. Subramanian A, Ranganathan P, Diamond SL. Nuclear targeting peptide scaffolds for lipofecdon of nondividing mammalian cells. Nat Biotech 1999;17:873-7
16. Ma H, Zhu J, Maronski M, et al. Non-classical nuclear locatization signal peptides for high efficiency lipofection of primary neurons and neuronal cell lines. Neuroscience 2002;112(1):1-5
17. Dean DA. Import of plasmid DNA into the nucleus is sequence specific. Exp Cell Res 1997;230:293-302
18. Wilson GI, Dean BS, Wang G, et al. Nuclear import of plasmid DNA in digitonin-permeabilized cells requires both cytoplasmic factors and specific DNA sequences. J Biol Chem 1999;274(31):22025-32
19. Izaurralde E, Kann M, Pante N, et al. EMBO Workshop Report Viruses, microorganisms and scientists meet the nuclear pore Leysin, VD, Switzerland, February 26 - March 1, 1998. EMBO J 1999;18(2):289-96
20. Kaneda Y, Tabata Y. Non-viral vectors for cancer therapy. Cancer Sci 2006;97(5):348-54
21. Wagner E, Plank C, Zatloukal K, et al. Influenza virus hemagglutinin HA-2 N-terminal fimogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: toward a synthetic virus-like gene-transfer vehicle. Proc Natl Acad Sci USA 1992;89:7934-8
22. Kaneda Y, Iwai K, Uchida T. Increased expression of DNA cointroduced with nuclear protein in adult rat liver. Science 1989;243:375-8
23. Saeki Y, Matsumoto N, Nakano Y, et al. Development and characterization of cationic liposomes conjugated with HVJ (Sendai virus): reciprocal effect of cationic lipid for in vitro and in vivo gene transfer. Hum Gene Tler 1997;8(17):2133-41
24. Okada Y. Sendai virus-induced cell fusion. Methods Enzymol 1993;221:1841
25. Kido H, Yokogoshi Y, Sakai K, et al. Isolation and charaaerization of a novel trypsin-like protease found in rat bronchiolar epithelial Clara cells. A possible activator of the viral fusion glycoprotein. J Biol Chem 1992;267(19):13573-9
26. Gotoh B, Ogasawara T, Toyoda T, et al. An endoprotease homologous to the blood clorting factor X as a determinant of viral tropism in chick embryo. EMBO J 1990;9(4):4189-95
27. Maeda T, Ohnishi S. Activation of influenza virus by acidic media causes hemolysis and fusion of erythrocytes. FEBS Lett 1980;122(2):283-7
28. Blumenthal R, Bali-Puri A, Walter A, et al. pH-dependent fusion of vesicular stomatitis virus with Vero cells. Measurement by dequenching of octadecyl rhodamine fluorescence. J Biol Chem 1987;262(28):13614-9
29. Marsh M, Bolzau E, Helenius A. Penetration of Semliki Forest virus from acidic prelysosomal vacuoles. Cell 1983;32(3):931-40
30. Suvanasuthi S, Tonai K, Kaneda Y. Rapid transport of plasmid DNA into the nucleolus via actin depolymerization using the HVJ envelope vector. J Gene Med 2007;9:55-62
31. + memory T cells specific for a subdominant epitope following Sendai virus infection. J Immunol 1997;158(9):4301-9
32. Kaneda Y, Nakajima T, Nishikawa T, et al. Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Mol Ther 2002;60:219-26
33. Kaneda Y, Yamamoto S, Nakajima T. Development of HVJ envelope vector and its application to gene therapy. In: Huang L, Hung M-C, Wagner E, editors. Non-Viral Vectors for Gene Therapy. Elsevier Academic Press; 2005. p. 307-32
34. Oldfield EH, Ram Z, Culver KW, et al. Gene therapy fbr the treatment of brain tumors using intra-rumoral transduction with the thymidinte kinase gene and intravenous gancidovir. Hum Gene Ther 1993;4:39-69
35. Oshima K, Shimamura M, Mizuno S, et al. Intrathecal injection of HVJ-E containing HGF gene to cerebrospinal fluid can prevent and ameliorate hearing impairment in rats. FASEB J 2004;18:212-4
36. Shimamura M, Morishita R, Endoh M, et al. HVJ-envelope vector for gene transfer into central nervous system. Biochem Biophys Res Commun 2003;300(2):464-71
37. Nakamura T, Nishizawa T, Hagiya M, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989;342(6248):440-3
38. Honda S, Kagoshima M, Wanaka A, et al. Localization and functional coupling of HGF and c-Met/HGF receptor in rat brain: implication as neurotrophic factor. Brain Res Mol Brain Res 1995;32(2):197-210
39. Maina F. Klein R. Hepatocyte growth factor, a versatile signal for developing neurons. Nat Neurosci 1999;2:213-7
40. Shimamura M, Sato N, Ogihara T, et al. A novel therapeutic strategy to treat brain ischemia: over-expression of hepatocyte growth factor gene reduced ischemic injury without cerebral edema in rat model. Circulation 2004;109:424-31
41. Dorsett Y, Tuschl T. siRNAs: applications in functional genomics and potential as therapeutics. Nat Rev Drug Discov 2004;3(4):318-29
42. Sioud M. Ribozyme-and siRNA-mediated mRNA degradation: a general introduction. Methods Mol Biol 2004;252:1-8
43. Roberts JJ, Kotsaki-Kovatsi VP. Potentiation of sulphur mustard or cisplatin-incluced toxicity by caffeine in Chinese hamster cells correlates with formation of DNA double-strand breaks during replication on a damaged template. Mutat Res 1986; 165(3):207-20
44. Zdraveski ZZ, Mello JA, Marinus MG, et al. Multiple pathways of recombination define cellular responses to cisplatin. Chem Biol 2000;7:39-50
45. D'Andrea AD, Grompe M. The Fanconi anemia/BRCA pathway. Nat Rev Cancer 2003;3:23-34
46. Ito M, Yamamoto S, Nimura K, et al. Rad51 ARNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin. J Gene Med 2005;7:1044-52
47. Morishita R, Gibbons GH, Horiuchi M, et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA 1995;92(13):5855-9
48. Morishita R, Sugimoto T, Aoki M, et al. In vivo transfection of cis element "decoy" against NF-κB binding site prevented myocardial infarction as gene therapy. Nat Med 1997;3:894-9
49. Nakamura H, Aoki M, Tamai K, et al. Prevention and regeneration of atopic dermatitis by ointment containing NF-κB decoy oligonucleoticles in NC/Nga atopic mouse model. Gene Ther 2002;9:1221-9
50. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347(6):417-29
51. Bouma G, Strober W The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003;3(7):521-33
52. Fichtner-Feigl S, Fuss IJ, Preiss JC, et al. Treatment of murine Th1-and Th2-mediated inflammatory bowel disease with NF-κB decoy oligonudeotides. J Clin Invest 2005;115(11):3057-71
53. Fichter-Feiql S, Strober W, Kawakami K, et al. IL-13 signaling through the IL-13 alpha.2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 2006; 12:99-106
54. Yasuoka E, Oshima K, Tamai K, et al. Needleless intranasal administration of HVJ-E containing allergen attenuates experimental allergic rhinitis. J Mol Med 2007;85:279-88
55. Takata K, Kitamura Y, Yanagisawa D, et al. Microglial. transplantation increases amyloid-beta clearance in Alzheimer model rats. FEBS Lett 2007;581:475-8
56. NishikawaT, Nakagami H, Matuki A, et al. Development of high-throughput functional screening of therapeutic genes using a hemagglutinating virus of Japan envelope vector. Hum Gene T'her 2006;17:470-5
57. Kitamura T, Koshino Y, Shibata F, et al. Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics. Exp Hematol 2003;31(11):1007-14
58. Scobar NM, Haupt S, Thow G, et al. High-throughput viral expression of cDNA-green fluorescent protein fusions reveals novel subcellular addresses and identifies unique proteins that interact with plasmodesmata. Plant Cell 2003;15:1507-23
59. Saito Y, Nakagami H, Kurooka M, et al. Cold shock domain protein A represses angiogenesis and lymphangiogenesis via inhibition of serum response element. Oncogene; In Press
60. Kurooka M, Kaneda Y. Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells. Cancer Res 2007;67:227
61. Fujihara A, Kurooka M, Miki T, et al. Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation. Cancer Immunol Immunother, In Press
62. Kawano H, Komaba S, Yamasaki T. et al. New potential therapy for orthoropic bladder carcinoma by combining HVJ envelope with doxorubicin. Cancer Chemother Pharmacol; In Press 2007
63. Marshall E. Clinical trials: gene therapy death prompts review of adenovirus vector. Science 1999;286(5448):2244
64. Kaiser J. Gene therapy: seeking the cause of induced leukemias in X-SCID trial. Science 2003;299:495
65. Masaki I, Yonemitsu Y, Yamashita A, et al. Angiogenic gene therapy for experimental critical limb ischemia acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2. Am Heart Assoc 2002;90:966-73
66. Blattman JN, Greenberg PD. Cancer Immunotherapy: A Treatment for the Masses. Volume 305. American Association for the Advancement of Science; 2004. p. 200-5
67. Ahmad M, Rees RC, Ali SA. Escape from immunotherapy. possible mechanisms that influence tumor regression/progression. Cancer Immunol Immunother 2004;53(10):844-54
68. Pawelec G. Immunotherapy and immunoselection: tumour escape as the final hurdle. FEBS Lett 2004;567(1):63-6
69. Tomasi TB, Magner WJ, Khan ANH. Epigenetic regulation of immune escape genes in cancer. Cancer Immunol Immumother 2006;55(10):1159-84
70. Banat GA, Christ O, Cochlovius B, et al. Tumour-induced suppression of immune response and its correction. Cancer Immunol Immunother 2001;49(11):573-86
71. Cui Z, Han SJ, Vangasseri DP, Huang L. Immunostimulation mechanism of LPD nanoparticle as a vaccine carrier. Mol Pharm 2005;2(1):22-8
72. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006;5(6):471-84
73. Kawano H, Komaba S, Kanamori T, et al. A new therapy for highly effective tumor eradication using HVJ-E combined with chemotherapy. BMC Med 2007;5:28
74. Mima H, Tomoshige R, Kanamori T, et al. Biocompatible polymer enhances the in vitro and in vivo transfection efficiency of HVJ envelope vector. J Gene Med 2005;7:888-97
75. Mima H, Yamamoto S, Ito M, et al. Targeted chemotherapy against intraperitoneally disseminated colon carcinoma using a cationized gelatin-conjugated HVJ envelope vector. Mol Cancer Ther 2006;5:1021-8
76. Kawachi M, Tamai K, Saga K, et al. Development of tissue-targeting HVJ envelope vector for successful delivery of therapeutic gene to mouse skin. Hum Gene Ther 2007;18:881-94
77. HVJ by viral gene engineering. Based on the method, HVJ-E vector containing single-chain antibody recognizing basal cells of skin was constructed. The vector efficiently delivered type VII collagen gene to basal cells of the skin of epidermolysis bullosa model mouse.
78. Saga K, Tamai K, Kawachi M, et al. Functional modification of Sendai virus by siRNA. J Biotechnol; In Press
79. Shimbo T, Kawachi M, Saga K, et al. Development of a transferrin receptor-targeting HVJ-E vector. Biochem Biophys Res Commun; 2007;364(3):423-8
80. Slobod KS, Shenep JL, Lujan-Zilbermann J, et al. Safety and immunogenicity of intranasal murine parainfluenza virus type I (Sendai virus) in healthy human adults. Vaccine 2004;22:3182-6